Weight loss at the first month of palliative chemotherapy predicts survival outcomes in @entity1 with advanced XXXX .

@entity1 @entity356 @entity353
BACKGROUND: Weight loss during chemotherapy is a significant prognostic factor for poor survival in @entity1 with advanced @entity356 (AGC). However, in most studies, @entity353 was measured at the end of chemotherapy, limiting its clinical use. In this study, we evaluated whether @entity353 during the first month of chemotherapy could predict survival outcomes in @entity1 with AGC. METHODS: We analyzed 719 @entity1 with metastatic or recurrent AGC who were receiving palliative chemotherapy. We calculated the initial body mass index (BMIi), percent @entity353 after 1  month of chemotherapy (  W 1m), percent @entity353 after last administration of chemotherapy (  W end), and average @entity353 per month during chemotherapy (  W/m). We correlated these data with overall survival (OS) by receiver-operating characteristic (ROC) curves and Kaplan-Meier curves, and performed a subgroup analysis using Cox regression. RESULTS: The probabilities of longer OS had stronger correlations with   W/m and   W 1m than with   W end or BMIi. A significant positive correlation between   W 1m and   W/m (r (2)  =  0.591, p  <  0.001) was observed. Median OS of @entity1 with   W 1m more than 3  % was significantly shorter than in @entity1 with less @entity353 (OS: 9.7 vs. 16.3  months, p  <  0.001). Subgroup analysis revealed that   W 1m accompanied poor survival irrespective of other clinical characteristics. CONCLUSION: Weight loss at the very first month of palliative chemotherapy could predict unfavorable survival outcomes in AGC.
